Molecular predictors of metastasis in patients with prostate cancer

Lin, Jundong; Zhuo, Yangjia; Zhang, Yixun; Liu, Ren; Zhong, Weijie

doi:10.1080/14737159.2023.2187289

Cited by 3 publications

(2 citation statements)

References 221 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, some developing countries or poor regions may face the challenges of limited funding and inadequate research conditions, resulting in a relative lag in scientific research. In this way, a contradiction has arisen between developing countries with limited medical technology but high PC morbidity and mortality and developed countries with advanced medical technology but reduced PC morbidity and mortality[ 25 , 26 ]. Therefore, developed countries should proactively conduct international exchanges and cooperation in the field of PCLM to promote the sharing of data, funds and equipment, technology and methods, and the establishment of international cooperation networks.…”

Section: Discussionmentioning

confidence: 99%

What should be the future direction of development in the field of prostate cancer with lung metastasis?

Huang,

Chen,

et al. 2023

World J Clin Oncol

View full text Add to dashboard Cite

BACKGROUND Since the start of the 21 st century, prostate cancer with lung metastasis (PCLM) has accumulated significant scientific research output. However, a systematic knowledge framework for PCLM is still lacking. AIM To reconstruct the global knowledge system in the field of PCLM, sort out hot research directions, and provide reference for the clinical and mechanism research of PCLM. METHODS We retrieved 280 high-quality papers from the Web of Science Core Collection and conducted a bibliometric analysis of keywords, publication volume, and citation frequency. Additionally, we selected differentially expressed genes from global high-throughput datasets and performed enrichment analysis and protein-protein interaction analysis to further summarize and explore the mechanisms of PCLM. RESULTS PCLM has received extensive attention over the past 22 years, but there is an uneven spatial distribution in PCLM research. In the clinical aspect, the treatment of PCLM is mainly based on chemotherapy and immunotherapy, while diagnosis relies on methods such as prostate-specific membrane antigen positron emission tomography/computed tomography. In the basic research aspect, the focus is on cell adhesion molecules and signal transducer and activator of transcription 3, among others. Traditional treatments, such as chemotherapy, remain the mainstay of PCLM treatment, while novel approaches such as immunotherapy have limited effectiveness in PCLM. This study reveals for the first time that pathways related to coronavirus disease 2019, cytokine-cytokine receptor interaction, and ribosome are closely associated with PCLM. CONCLUSION Future research should focus on exploring and enhancing mechanisms such as cytokine-cytokine receptor interaction and ribosome and improve existing mechanisms like cadherin binding and cell adhesion molecules.

show abstract

Section: Discussionmentioning

confidence: 99%

What should be the future direction of development in the field of prostate cancer with lung metastasis?

Huang,

Chen,

et al. 2023

World J Clin Oncol

View full text Add to dashboard Cite

show abstract

“…The evaluation of the expression of specific biomarkers (microRNAs, lncRNAs, proteins, etc.) has produced important results for predicting the occurrence/progression of several cancerous [9][10][11][12][13] and non-cancerous [14][15][16] diseases. Moreover, some biomarkers have shown the ability to predict recurrence, chemoresistance, progression and metastasis development in several types of cancers, including ovarian cancer [17][18][19][20][21].…”

mentioning

confidence: 99%

Ovarian Cancer: Advances in Pathophysiology and Therapies

Tossetta

Inversetti

2023

IJMS

View full text Add to dashboard Cite

show abstract

Androgen Signaling in Prostate Cancer: When a Friend Turns Foe

Pandey,

Sabharwal,

Tripathi

et al. 2025

EMIDDT

View full text Add to dashboard Cite

Abstract:: Androgen (AR) signaling is the main signaling for the development of the prostate and its normal functioning. AR is highly specific for testosterone and dihydrotestosterone, significantly contributing to prostate development, physiology, and cancer. All these receptors have emerged as crucial therapeutic targets for PCa. In the year 1966, the Noble prize was awarded to Huggins and Hodge for their groundbreaking discovery of AR. As it is a pioneer transcription factor, it belongs to the steroid hormone receptor family and consists of domains, including DNA binding domain (DBD), hormone response elements (HRE), C-terminal ligand binding domain (LBD), and N-terminal regulatory domains. Structural variations in AR, such as AR gene amplification, LBD mutations, alternative splicing of exons, hypermethylation of AR, and co- regulators, are major contributors to PCa. It’s signaling is crucial for the development and functioning of the prostate gland, with the AR being the key player. The specificity of AR for testosterone and dihydrotestosterone is important in prostate physiology. However, when it is dysregulated, AR contributes significantly to PCa. However, the structural variations in AR, such as gene amplification, mutations, alternative splicing, and epigenetic modifications, drive the PCa progression. Therefore, understanding AR function and dysregulation is essential for developing effective therapeutic strategies. Thus, the aim of this review was to examine how AR was initially pivotal for prostate development and how it turned out to show both positive and detrimental implications for the prostate

show abstract

Molecular predictors of metastasis in patients with prostate cancer

Cited by 3 publications

References 221 publications

What should be the future direction of development in the field of prostate cancer with lung metastasis?

What should be the future direction of development in the field of prostate cancer with lung metastasis?

Ovarian Cancer: Advances in Pathophysiology and Therapies

Androgen Signaling in Prostate Cancer: When a Friend Turns Foe

Contact Info

Product

Resources

About